AstraZeneca PLC Form 6-K: CEO Pascal Soriot Gifts 136,537 Shares

Here are the key insights extracted from the financial report, specifically the Form 6-K for AstraZeneca PLC regarding director shareholdings:

1. Date of Report: The report is dated November 10, 2025, and pertains to events occurring on November 7, 2025.
2. Company Overview: AstraZeneca PLC is a global biopharmaceutical company focused on the development and commercialization of medicines in various therapeutic areas, including Oncology, Rare Diseases, and BioPharmaceuticals.
3. Director Transaction:

• Person Involved: Pascal Soriot, Executive Director and CEO of AstraZeneca.
• Details of Transaction: On November 7, 2025, Soriot ceased to be beneficially interested in 136,537 ordinary shares of AstraZeneca, which he gifted to family members for nil consideration (i.e., no payment was made for the shares).

4. Regulatory Compliance: The transaction was reported in accordance with the EU Market Abuse Regulation, which is part of UK law.
5. Nature of Transaction: The transaction is classified as a "gift of shares," indicating a transfer of ownership without a sale price.
6. Financial Instrument Details:

• Type of Instrument: Ordinary Shares of $0.25 each.
• Identification Code: GB0009895292.

7. Volume and Price:

• Volume of Shares Transferred: 136,537 shares.
• Price of Transaction: Not applicable as this was a gift (nil consideration).

8. Place of Transaction: The shares were transferred outside of a trading venue, reflecting a private transaction.
9. Reporting Compliance: The report confirms that AstraZeneca files annual reports under Form 20-F and has acknowledged the submission of the Form 6-K in compliance with SEC regulations.

This report highlights a significant insider transaction involving the CEO, which may signal personal financial decisions that could influence perceptions of the company's leadership and shareholder dynamics.